EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis-Reference-Cited by-同舟云学术

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis

Published:2017-09 Issue:9 Volume:4 Page:e414-e423
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Luft Thomas,Benner Axel,Jodele Sonata,Dandoy Christopher E,Storb Rainer,Gooley Ted,Sandmaier Brenda M,Becker Natalia,Radujkovic Aleksandar,Dreger Peter,Penack Olaf

Publisher

Elsevier BV

Subject

Hematology

Reference36 articles.

1. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review;Ali;Biol Blood Marrow Transplant,2016

2. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth;Penack;J Natl Cancer Inst,2010

3. Initiation of acute graft-versus-host disease by angiogenesis;Riesner;Blood,2017

4. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease;Biedermann;Lancet,2002

5. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease;Ertault-Daneshpouy;Blood,2004

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EASIX (endothelial activation and stress index) predicts mortality in patients with coronary artery disease;Clinical Research in Cardiology;2024-09-10

2. Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies;Thrombosis Update;2024-09

3. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD;Blood;2024-08-29

4. Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation;Bone Marrow Transplantation;2024-08-08

5. Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide;Transplantation and Cellular Therapy;2024-08